HAVCR1 and kidney disorder: Ultimately, the most clinically translatable research path lies in conducting rigorously designed randomized controlled clinical trials to evaluate whether clinical intervention strategies targeting the reduction of TG (e.g., using fibrate drugs, ω-3 fatty acids, or intensive lifestyle interventions) or TC can effectively reduce urinary KIM-1 levels in high-risk individuals and ultimately achieve the clinical goal of slowing kidney disease progression.